Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-4673
Fax+1 214-645-2615
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 3 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jue Wang, MD is an oncologist in Dallas, Texas. He is currently licensed to practice medicine in Texas and Arizona. He is affiliated with University of Texas Southwestern Medical Center and is an Assistant Professor at University of Nebraska Medical.
Education & Training
University of Texas Medical Branch HospitalsFellowship, Medical Oncology, 2005 - 2007- University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2002 - 2005
Suzhou Medical CollegeClass of 1990
Certifications & Licensure
TX State Medical License 2023 - 2027
AZ State Medical License 2014 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification MEDSEEK Empower, SymphonyCare, LLC, 2013-2017
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2013-2017
Publications & Presentations
PubMed
- Successful Management of Disseminated Intravascular Coagulation in Metastatic Castrate-Resistant Prostate Cancer With Lutetium-177: A Case Report and Review of the Lit...Jie Zheng, Chidera Ibezue, Nghi Nguyen, Qi Cai, Qian Qin
Cureus. 2024-12-01 - 1 citationsOn reactive Ion Etching of Parylene-C with Simple Photoresist Mask for Fabrication of High Porosity Membranes to Capture Circulating and Exfoliated Tumor Cells.Inad Rabadi, David Carpentieri, Jue Wang, Frederic Zenhausern, Jian Gu
Micromachines. 2024-04-13 - 5 citationsTrastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.Roisin M Connolly, Victoria Wang, David M Hyman, Petros Grivas, Edith P Mitchell
Clinical Cancer Research. 2024-04-01
Press Mentions
Comparison of Clinicopathological Characteristics and Response to Neoadjuvant Systemic Therapy in Patients with HER2-Low-Positive and HER2-Zero Breast CancerJanuary 19th, 2023
NMPA Approves IND Application for CT103A, a Fully-Human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-Developed by IASO BIO and Innovent BiologicsOctober 2nd, 2019- Clinical Results of Fully Human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-Developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual MeetingsJune 19th, 2019
